Gastrointestinal (GI) malignancies account for approximately one-quarter of new cancer diagnoses and more than one-third of cancer-related deaths worldwide, yet as of August 2026, only one CAR-T therapy has received regulatory approval for a solid tumor indication anywhere in the world. The recent CT041-ST-01 phase II...
Mariam I. M. Ismail, Noran Al-Gizey, Zaid Alabed et al.· Pharmaceuticals· 0 citations
Gastrointestinal (GI) cancers remain a leading cause of cancer-related morbidity and mortality worldwide despite major advances in systemic therapy. Although immune checkpoint inhibitors have improved outcomes in selected biomarker-defined populations, most GI malignancies, including microsatellite-stable colorectal ca...
Mariam I. M. Ismail, Noran Al-Gizey, Ebtesam Al-Najjar et al.· Frontiers in Oncology· 0 citations
This review explains how cancer cells bypass standard therapies and highlights next-generation immune targets currently being developed to overcome resistance, and examines how combining new immune-boosting drugs with traditional treatments like chemotherapy, radiation, and novel targeted therapies can weaken cancer de...
